Menu Back toLS30: Paradigm Shift of Clinical Trial Site Costs ~Effort to Address the Diversifying Changes in Clinical Trial Design~

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

LS30: Paradigm Shift of Clinical Trial Site Costs ~Effort to Address the Diversifying Changes in Clinical Trial Design~

Session Chair(s)

Kenji  Udo

Kenji Udo

  • Group Lead of Clinical Operations
  • Pfizer R&D Japan G.K., Japan

Speaker(s)

Toshiyuki  Okada

Toshiyuki Okada

  • Team Leader, Clinical Operation and Innovation Group
  • Astellas Pharma Inc., Japan
Keiichi  Inaizumi, MSc

Keiichi Inaizumi, MSc

  • Clinical Project Management Group/ Japan Clinical Project Manager
  • Pfizer R&D Japan, Japan

Contact us